BioPharmSignal logoBioPharmSignal

Biotech News

Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences

Nurix Therapeutics (NRIX)Nurix TherapeuticsPartnership

Two-year extension builds on productive relationship established in 2019 Nurix continues to retain co-development and 50/50 profit sharing options on up to two programs in the United States BRISBANE, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc.

Related news

NRIXNurix Therapeutics2026-09-29 11:00 EST

Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer

NRIXNurix Therapeutics2026-10-07 05:00 EST

Nurix Therapeutics Announces First Patient Enrolled in Phase 1b/2 Combination Study of Bexobrutideg in Chronic Lymphocytic Leukemia

MGNXMacroGenics2026-08-11 20:05 EST

MacroGenics Announces Achievement of $10 Million Milestone Following Gilead’s Exercise of Option to License Preclinical Bispecific Program

IDYAIDEAYA Biosciences2026-08-19 10:00 EST

IDEAYA Biosciences Announces Clinical Collaboration with Genentech in MTAP-Deleted KRAS G12D-Mutant Pancreatic Cancer

REGNRegeneron Pharmaceuticals2026-10-01 05:00 EST

Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies

ALECAlector2026-10-05 11:00 EST

Alector Enters Global License Agreement with Genentech for Brain Penetrant GCase Enzyme Replacement Therapy for Parkinson’s Disease and Other Neurodegenerative Diseases

SNYSanofi2026-10-01 05:00 EST

Press Release: Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies

SNYSanofi2026-09-14 13:03 EST

Press Release: Sanofi and Cheplapharm to create new strategic partnership in mature medicines

CGEMCullinan Therapeutics, Inc.2026-10-01 23:30 EST

New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA Real-Time Oncology Review Program

KURAKura Oncology2026-09-09 11:00 EST

Kura Oncology Launches Caspian Therapeutics with $50 Million Financing to Advance Menin Inhibition as a Potential Disease-Modifying Approach for Diabetes

View all latest news

Nurix Therapeutics

Targeted Protein Degradation Nurix Therapeutics develops medicines that use the cell’s ubiquitin-proteasome system to remove disease-causing proteins. Its portfolio includes wholly owned degraders and programs partnered with large pharmaceutical companies. Bexobrutideg Bexobrutideg is an oral BTK degrader being advanced as a potential...

Recent company news

NRIXNurix Therapeutics2026-10-07 05:00 EST

Nurix Therapeutics Announces First Patient Enrolled in Phase 1b/2 Combination Study of Bexobrutideg in Chronic Lymphocytic Leukemia

NRIXNurix Therapeutics2026-10-05 11:00 EST

Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences

NRIXNurix Therapeutics2026-09-29 11:00 EST

Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer

NRIXNurix Therapeutics2026-09-01 12:00 EST

Nurix Therapeutics to Participate in Upcoming September Investor Conferences

NRIXNurix Therapeutics2026-08-20 11:00 EST

Nurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources Officer

Stock data

Close
22.60 USD
Market cap
1.69B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States